Redeye recently initiated coverage of Senzime, a Swedish medtech company, specialising in quantitative neuromuscular patient monitoring with its flagship device, the TetraGraph system. We interviewed analyst Gustaf Meyer, who talked us through the investment case.

Läs mer på Redeye

Ämnen i artikeln


Senzime

Senast

6,20

1 dag %

−4,02%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån